Bladder cancer detection kit

genomic DNAurinestool

Bladder cancer is one of the most common malignancies but the corresponding diagnostic methods are either invasive or limited in specificity and/or sensitivity. DNA methylation is present in all bladder tumors and can be detected in urine specimens. DNA Methylation can be a novel marker of prognosis for tumor therapy, which is also a reversible process in which inactivated tumor suppressor genes are expressed through demethylation to exert a tumor suppressor effect. Therefore, demethylation can be used as a new direction in cancer treatment to monitor the dynamics of the disease. Intended Use This kit is a real-time PCR assay for qualitative detection of DNA methylation in gene PCDH17, POU4F2 and PENK in human genomic DNA extracted from stool sample. General Specification Precision: CV <5% LoD: 1% of PCDH17, POU4F2 and PENK methylation in the background of 5ng human genomic DNA Packing Specifications 24 tests/kit (non-single test/tube) - 48 tests/kit (non-single test/tube)